Journey Medical's Q1 2026: Amrozi Rosacea Treatment Shines

Journey Medicals Q1 2026 earnings show a robust performance, with total revenue surging 21% to $16M. Amrozi, their rosacea treatment, shines with a 187% increase in revenue to $6.3M. Despite harsh winter weather, prescriptions grew 11% and Amrozis unique prescribers rose to 3,700. The company secured deals with major pharmacy benefit managers, covering 85% of U.S. commercial lives. Financials improved with a 61% gross margin, narrowed net loss, and positive adjusted EBITDA. Journey Medical plans to add sales reps, launch new products, and expects positive adjusted EBITDA for the next few years. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/7422eac820d9608d